We are happy to share the latest Community Statement issued by Biogen about the Phase 2/3 DEVOTE study evaluating the safety and efficacy of a higher dose regimen of nusinersen for the treatment of spinal muscular atrophy (SMA).
We are thrilled to announce our collaboration with EUPATI, an organisation committed to educating and empowering patients and their advocates.
We are excited to announce our new partnerships with Rare Revolution Magazine and SMA News Today, two leading digital health media outlets dedicated to the rare disease and SMA communities. These collaborations are set to ensure global outreach by amplifying the voices of SMA patients and delivering patient-centered content that truly matters. Together, we are committed to raising awareness and providing essential resources for Spinal Muscular Atrophy.
We are excited to share with all of you our Annual Report 2023!